Between 1947 and 1971, diethylstilbestrol (DES) was widely used in the United States for diabetic women during pregnancy and to treat threatened abortion. It is estimated that 2-3 million fetuses were exposed. A relationship between fetal DES exposure and clear cell carcinoma of the vagina was later discovered, and a number of other related anomalies have since been noted. In one-third of all exposed women, there are changes in the vagina (adenosis, septa), cervix (deformities and hypoplasia of the vaginal portion of the cervix), or uterus (T-shaped cavity).
At present, all exposed women are advised to have an initial colposcopic examination to outline vaginal and cervical areas of abnormal epithelium, followed by cytologic examination of the vagina (all four quadrants of the upper half of the vagina) and cervix at yearly intervals. Lugol’s iodine stain of the vagina and cervix will also outline areas of metaplastic squamous epithelium.
Many women are not aware of having been exposed to DES. Therefore, in the age groups at risk (30-56 years), examiners should pay attention to structural changes of the vagina and cervix that may signal the possibility of DES exposure and indicate the need for follow-up.
The incidence of clear cell carcinoma is approximately one in 1000 exposed women, and the incidence of cervical and vaginal intraepithelial neoplasia (dysplasia and carcinoma in situ) is twice as high as in unexposed women. DES daughters have more difficulty conceiving and have an increased incidence of early abortion, ectopic pregnancy, and premature births. In addition, mothers treated with DES in pregnancy appear to have a small increase in the incidence of breast cancer, beginning 20 years after exposure.
Palmer JR et al: Infertility among women exposed prenatally to diethylstilbestrol. Am J Epidemiol 2001;154:316.
Revision date: July 4, 2011
Last revised: by Janet A. Staessen, MD, PhD